A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

NCT00739661 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Vismodegib 150 mg
DRUG: Placebo to vismodegib

Sponsor

Genentech, Inc.